Collaboration Agreement

Angle PLC
03 August 2004


For Immediate Release                                          3 August 2004




ANGLE plc

                     COLLABORATION WITH UNIVERSITY OF YORK

                       FOUNDING OF IVF TECHNOLOGY VENTURE



ANGLE plc, the venture management and consulting company specialising in the
commercialisation of technology, is pleased to announce that ANGLE Technology
has signed a collaboration agreement with the University of York and its
emerging biotech business Cellutions Ltd.



Under the new agreement, ANGLE has an option for 18 months to intellectual
property (IP) developed in the laboratory of Professor Henry Leese.   This IP
promises to enable doctors to identify the viability of embryos leading to
successful pregnancy in the first stage of IVF treatment. The technology, based
on the analysis of the embryo's amino acid profile, has the potential to deliver
major financial and emotional cost benefits by making single embryo transfer a
realistic target and thereby reducing the incidence of multiple births.



As part of its Venture activity, ANGLE has formed a new company, Novocellus Ltd,
to manage the technology commercialisation.  In accordance with the Progeny(R)
process, Novocellus will be fully funded by ANGLE.  Typically, Progeny(R)
companies require funding of £500,000 during the option period.



Commenting on the collaboration with ANGLE, the University's Sue Final, said:



'We are delighted that this collaboration with ANGLE provides the opportunity to
realise this technology and bring it to the market place, offering hope of
successful outcomes for thousands of couples undergoing IVF while reducing the
risks associated with multiple births.'



ANGLE's Chief Executive Andrew Newland said:



'It is particularly exciting to have founded Novocellus, as it represents not
only another leading-edge technology company for our Venture activity, and a
major source of cost savings for the health service, but also a promise of
significant help to those considering IVF treatment.'



For further information


ANGLE plc                                      01483 295830
Andrew Newland, Chief Executive
Dawson Buck, Deputy Chief Executive


Buchanan Communications                        020 7466 5000
Richard Darby, Suzanne Brocks



Notes to Editors



Founded in 1994, ANGLE is an international venture management and consulting
company focusing on the commercialisation of technology and the development of
technology-based industry. ANGLE creates, develops and advises technology
businesses on its own behalf and for its clients.




                      This information is provided by RNS
            The company news service from the London Stock Exchange